Background The acquisition costs of biologic drugs are often considered to be relatively high compared with those of nonbiologics. However, the total costs of delivering these drugs also depend on the cost of administration. Ignoring drug administration costs may distort resource allocation decisions because these affect cost effectiveness. Objectives The objectives of this systematic review were to develop a framework of drug administration costs that considers both the costs of physical administration and the associated proximal costs; and, as a case example, to use this framework to evaluate administration costs for biologics within the UK National Health Service (NHS). Methods We reviewed literature that reported estimates of administration costs for biologics within the UK NHS to identify how these costs were quantified and to examine how differences in dosage forms and regimens influenced administration costs. The literature reviewed were identified by searching the Centre for Review and Dissemination Databases (DARE, NHS EED and HTA); EMBASE (The Excerpta Medica Database); MEDLINE (using the OVID interface); Econlit (EBSCO); Tufts Medical Center Cost Effectiveness Analysis (CEA) Registry; and Google Scholar. Results We identified 4,344 potentially relevant studies, of which 43 studies were selected for this systematic review. We extracted estimates of the administration costs of biologics from these studies. We found evidence of variation in the way that administration costs were measured, and that this affected the magnitude of costs reported, which could then influence cost effectiveness. Conclusions Our findings suggested that manufacturers of biologic medicines should pay attention to formulation issues and their impact on administration costs, because these affect the total costs of healthcare delivery and cost effectiveness.
ically administering a drug, plus proximal costs incurred before or after physical administration.
• Drug administration costs vary by route of administration. On average, administration costs are higher for biologics given intravenously when compared with those given by intramuscular or subcutaneous routes.
• We found evidence of variation in the way that administration costs were measured in research studies.
• Formulation issues, drug administration and healthcare delivery costs should be considered as early as possible when making manufacturing and R&D decisions.
in the case of bortezomib (Velcade Ò ) and £70,000 per patient per year for bevacizumab (Avastin Ò ), cannot be sustained in publicly funded healthcare systems such as the UK National Health Service (NHS). While acquisition costs of biologics are considered to be relatively high compared with those of other drugs, the costs of treating patients with these drugs also depends on the cost of administration, which can vary substantially and can be sizeable. It is feasible that a low-priced drug could have the same delivery costs as a high-priced drug once the administration costs are included. For example, two biologics A and B with acquisition costs of £7,889 and £9,980 per treatment cycle, respectively, will have roughly the same total delivery costs per cycle if biologic A, requiring 15 clinic visits or injections, incurs £3,195 in administration costs, while biologic B, requiring five clinic visits or injections, incurs £1,065 in administration costs.
For this reason, when assessing value for money it is important, first, that administration costs are accounted for, and second, that the full range of these costs are included. There are, obviously, other cost components in an economic evaluation. The value for money offered by a biologic product, relative to other treatment options, is typically measured by the incremental cost-effectiveness ratio, which compares the discounted total (lifetime) costs of delivering the biologic with the discounted total (lifetime) health effects it is expected to offer. The discounted (lifetime) costs of each option are estimated by summing the acquisition costs determined by the selling price; the associated administration costs determined by the chosen dosage regimen, route of administration and formulation; and future healthcare-related costs, which are, in part, determined by the clinical effectiveness of that option. In this paper, we consider the relative importance of administration costs.
Following Aulton [3] , we categorized the routes of drug administration and associated dosage forms as: (i) oral routes, involving solutions, syrups, tablets and capsules; (ii) rectal routes, involving suppositories and ointments; (iii) topical routes, involving the use of ointments, creams, topical aerosols and transdermal patches; (iv) parenteral routes, involving intravenous, subcutaneous and/or intramuscular injections; (v) respiratory routes, involving the use of aerosols, inhalations and sprays; (vi) nasal routes, involving solutions and inhalations; (vii) conjunctival and intraocular routes, involving eye solutions, ointments and creams; and (viii) solutions, suspensions, ointments and creams administered via the ear. According to Speers and Bonnano [4] , oral formulations are those most preferred by patients and, in terms of the dosage regimen (frequency of administration), once daily dosing is most attractive to clinicians and patients. The authors have defined a hierarchy of drug (re)formulation, which ranks modes of administration in the following order of increasing 'attractiveness': intravenous injections, intramuscular injections, subcutaneous injections, injectable sustained-release depot; transdermal (topical) applications; nasal and aerosol (respiratory) delivery; oral tablets or capsules administered more than once daily; and oral sustained-release formulations administered once daily.
For biologics, consideration of the most appropriate drug delivery system is critical, given that they consist of large molecules with delicate structural forms that have poor oral bioavailability. While oral biologics presents an opportunity for the industry in terms of the increase in market demand and sales (see Speers and Bonnano [4] ), they also present a significant challenge for biopharmaceutical manufacturing, as the delicate link between the macromolecular structure of biologics and their efficacy and safety profiles is such that moving from injectable to oral dosage forms may change the pharmacokinetic and/or pharmacodynamic properties. Although needle-free and oral delivery of biopharmaceuticals would seem to be a desirable focus for manufacturers, parenteral, injectable routes seem to be the most realistic routes for most biologics, at least in the short term. An investigation of biologic administration costs associated with injectable routes is needed.
The objectives of this study were to develop a framework of drug administration costs and, as a case example, to use this framework to evaluate the administration costs of biologics within the UK NHS. We conducted a systematic review of studies reporting biologic drug administration costs to provide empirical estimates of the costs of drug administration within the UK NHS. From the outputs of the literature review, we highlight the implications of our findings for research in biopharmaceutical manufacturing, e.g. how healthcare delivery costs and associated drug formulation issues may affect or influence manufacturing and R&D decisions.
A Framework of Drug Administration Costs
We adopted a broad definition of the components of administration costs, covering not just the physical administration of a biologic drug through one of the routes mentioned above but also the proximal costs incurred before or after physical administration of the drug. Figure 1 depicts our framework. This is intended to highlight the need to be explicit about what constitutes drug administration costs-to use our framework as a guide for thinking through all potential costs associated with the administration of biologics and other medical technologies. The framework is generic, as we do not expect the components of drug administration costs for biologics given via a particular route to differ markedly from those for non-biologics administered via the same route.
Literature Review Methods

Search Strategy and Study Selection
We searched the following electronic databases for relevant studies: the Centre for Review and Dissemination Databases (DARE, NHS EED and HTA); EMBASE (The Excerpta Medica Database); MEDLINE (using the OVID interface); and Econlit (EBSCO). We used search terms to identify studies providing estimates of the administration costs of biologics. The search terms that were used and the numbers of articles that were retrieved are detailed in Table 1 . Searches conducted using the Tufts Medical Center cost-effectiveness analysis (CEA) Registry and Google Scholar employed search terms that included: ''time'', ''motion'', ''drug'', ''administration'' and ''costs''. We combined the various search outputs, and the titles, abstracts and full texts of the resulting set of articles were assessed. Details of the studies that were identified and selected are shown in Fig. 2 .
In selecting studies for full-text assessment, we did not set any limits on the year of publication, and we used the following exclusion criteria when assessing the title, abstract and full text of the articles that were retrieved. We excluded non-UK studies, non-English language studies, conference abstracts, studies that did not report drug administration costs, studies that did not study biologics for human use, and newspaper articles. The full texts of the selected studies were assessed by both authors to determine whether a study should be included in or excluded from the systematic review. We excluded studies that did not consider or include drug administration costs in their analysis. We considered that these studies would have underestimated the total treatment costs and overestimated cost effectiveness, where it was evaluated. We also excluded studies that claimed to account for differences in administration costs but then did not report estimates, or where administration costs were considered but ignored. For those studies, we could not tell with surety what costs had been included or excluded.
For the purpose of this review, we defined biologics by using the European Medicines Agency (EMA) definition, stipulated under Directive 2001/83/EC, as active substances or medicinal products derived from a biological living system (plant, animal or microbial organism) no matter how 'small' the molecules are. This definition covers not just recombinant proteins, monoclonal antibodies, blood products, immunological products (vaccines, allergens, sera, etc.) and advanced technologies (gene and cell therapy products) but also analogous, semi-synthetic, biologically active substances or medicinal products of biological origins that do not belong to any of the main groups that are mentioned. Because of the broad EMA definition that was adopted, technologies evaluated in our set of studies were not restricted to commonly referred macromolecular (protein-based) products but also included 'biologics' or drugs that might be considered as 'small molecules'. Our literature review included studies that compared a biologic (or a combination of biologic-drug or biologic-device or biologic-drug-device) versus (i) single therapies or combinations of biologics; or (ii) small-molecule drugs or drug-device combinations. Also included in Proximal costs.
1. GP and clinic visits (outpatient and/or inpatient attendance) 2. Costs of education or training for selfadministration 3. Costs of pre-therapy counselling 4. Pharmacy costs (inventory, preparation and dispensing) 5. Pre-treatment medication costs 6. Costs of post-treatment, progress checks 7. Cost of (laboratory) tests, assessment or evaluations.
Costs of physical administration.
1. Staff (doctor/nurse) costs 2. Cost of equipment and consumables 3. Cost of concomitant medications. Fig. 1 Framework of drug administration costs. GP general practitioner the review were studies comparing different drug delivery systems irrespective of whether the active substance was a small-molecule chemically-synthesized drug or a biologic. Any disagreements as to which studies should be included in or excluded from the review were resolved via a series of discussions between the authors. We did not use any formal consensus methods, nor did we formally assess inter-reviewer agreement using, for example, Cohen's (chance-corrected) kappa statistic.
Components of drug administration costs
Data Extraction
For the selected studies, we extracted variables relating to study design and methodology; disease condition and patient population; interventions and the treatment alternatives compared; components of drug administration cost (proximal and physical administration); estimates of cost of administration (and the variation around this estimate, if reported); and the year to which costs applied. To ensure comparability of the estimates of costs of drug administration that were extracted, we employed the UK NHS Hospital and Community Health Services (HCHS) index [5] , which is a weighted average of two separate indices-the pay cost index and the health service cost index-to inflate and express all administration cost estimates extracted from the selected studies to year 2010 values.
Results
Description of Studies
We obtained 4,344 potentially relevant studies from our searches, of which 186 studies were identified as duplicates (Fig. 2) . From the remaining 4,158 studies, 3,976 were excluded upon assessment of the titles and abstracts. The main reasons for exclusion were if studies were conference abstracts or newspaper articles, review papers or editorials; and if studies were not written in English or where the country setting was not the UK. From the 191 potentially relevant studies we identified for full-text assessment, 43 studies were included in the literature review, and 148 studies were excluded on the basis that they did not provide evidence that was specific to the administration and use of biologics within the UK NHS.
Of the 43 studies that were reviewed, 15 evaluated anticancer treatments; nine evaluated vaccination and immunization programmes; eight focused on tumournecrosis-factor inhibitors for treatment of psoriatic arthritis, rheumatoid arthritis and Crohn's disease; four focused on prophylactic treatments (two of which were anticoagulants, one was for prevention of severe respiratory syncytial virus infection and the other study evaluated prophylactic treatment for haemolytic disease); three evaluated insulin analogues; and the remaining studies covered infertility treatments, antiviral treatment of hepatitis C, treatments for Parkinson's disease and treatments for control of bleeding in people with severe blunt trauma (see Online Resource 1 in the Electronic Supplementary Material).
Estimates of Administration Costs for Biologics
Within the UK NHS From the 43 selected studies, we counted the number of instances in which 'biologics' were administered by intravenous, subcutaneous, intramuscular, or oral routes. As expected, most of the biologics we studied were administered intravenously. Online Resource 1 shows that the administration costs of health technologies that were given intravenously tended to be higher than the costs of those administered subcutaneously, which were higher than the costs of those given intramuscularly, which in turn were higher than the costs of technologies given orally. For example, the administration cost of enoxaparin given subcutaneously was £26, while the administration cost for standard unfractionated heparin given intravenously was £104 [6] . The administration cost of oral vinorelbine 60 mg 148 studies excluded from the systematic review.
4344 potentially relevant studies identified from the initial literature searches.
Fig. 2 Study selection
Drug Administration Costs and Biopharmaceuticalswas £845, while the administration cost of intravenous vinorelbine 25 mg was £1,115 [7] . There were differences between the reviewed studies in the components of administration costs that were included (see Sect. 4.3) and variations in how studies reported drug administration costs. Notably, different measurement scales were used. For instance, some studies reported drug administration costs on a per-patient basis, while in other studies, costs were reported on a per-treatment basis over different time periods; some studies simply reported administration costs without specifying the measurement scale.
Taking into account the difficulties of finding a common measure of administration costs across all studies, we computed average estimates of administration costs across a selective set of 24 studies that reported estimates on a comparable scale, namely per unit of administration, e.g. per single injection or infusion. On the basis of the figures extracted from the selected studies, it appeared that giving biologics intravenously incurred the highest administration costs, while those for subcutaneous and intramuscular routes were of the same order of magnitude ( Table 2 ). The average administration cost (in year 2010 values) for 'biologics' administered intravenously was £213, which was almost six to eight times that for biologics given subcutaneously (£35) or intramuscularly (£27). Because these estimates were not derived from statistical analysis of primary data collected from the UK NHS, the figures should be considered as rough approximations of how much it cost to administer biopharmaceuticals via the various routes.
It might be argued that our approximations of administration costs for biologics within the UK NHS were taken from studies comparing different technologies for the treatment of different diseases and clinically indicated for different patient populations. Our estimates may therefore have hidden variations in drug administration costs by disease condition. For any biologic that was clinically indicated for two independent disease conditions, one would expect differences in administration costs if the dosage regimens for the treatment of these diseases were different. However, from the studies reviewed, we did not find any consistent evidence of variation in drug administration costs for a given biologic by disease condition.
To illustrate: infliximab, when used in rheumatoid arthritis, had administration costs of £148 per infusion according to Chen et al. [8] and £175 per infusion according to Jobanputra et al. [9] . According to Cummins et al. [10] , infliximab had administration costs of £128 when used in psoriatic arthritis. Note that while these adjusted figures (in year 2010 values) were quite close to each other, the unadjusted values reported in these studies were the same irrespective of whether infliximab was used for rheumatoid or psoriatic arthritis. Similarly, according to Woolacott et al. [11] and Bravo et al. [12] , infliximab had administration costs of £307 per infusion when used for psoriatic arthritis, but according to Dretzke et al. [13] , the infliximab administration cost was £285 per infusion when used in Crohn's disease. However, the unadjusted values reported in the studies were the same irrespective of whether infliximab was used for psoriatic arthritis or [34] ; the infliximab infusion cost (£148) [8] ; the administration cost of docetaxel per visit (£23) [36] ; the infusion cost of temsirolimus (£203) reported by Hoyle et al. [37] ; the administration cost of docetaxel (£209) [39] ; the cost of a hospital stay for chemotherapy delivery (£355) and the cost of outpatient attendance for chemotherapy (£292.41) [41] ; the infusion cost of infliximab (£307 = half rheumatology day case) [19, 20] ; the administration cost of gemcitabine (£153.50 = cost of a medical oncology outpatient visit); and the infusion cost component of the administration costs of a protracted infusion of 5-fluorouracil (£235) [17] Subcutaneous £35 This is based on the administration cost of enoxaparin (£26) [6] ; the administration cost of interferon alfa (£28) [46] ; the injection cost component (£25.33) of the administration costs of gonadotropins [18] ; the administration cost of peginterferon alfa (£59) [47] ; the average administration cost of enoxaparin (£13.75) [21] ; the weekly administration cost of etanercept (£24.42) derived from the figure (£293) reported by Bravo et al. [20] and Woolacott et al. [19] ; and the weekly administration costs (£34) of etanercept and adalimumab (£68) derived from the figure reported by Cummins et al. [10] Intramuscular £27 This is based on the administration cost of anti-D immunoglobulin G (£12) [51] ; the administration cost of hepatitis B vaccine (£20) [52] ; the administration cost of hepatitis B vaccine (£5.40) [57] ; the administration cost of influenza vaccine (£7.78) [53] ; the administration cost of 7-valent pneumococcal conjugate vaccine (£13) [55] ; the administration costs of vaccines for varicella infection (£13) [48] ; the administration cost of meningococcal serogroup C conjugate vaccine (£8.80) [58] ; the administration cost of antenatal anti-D prophylaxis (£4.40) [59] ; and the administration cost of palivizumab (£161) [56] Oral £10 This is based on three studies by Cassidy et al. [34] , Hoyle et al. [37] and Martin et al. [47] , which reported zero administration costs; the administration costs of rotavirus vaccines (£6.10) [22] ; and the unit administration costs of oral chemotherapies (£42) [7] Crohn's disease. On the other hand, the annual administration costs for rituximab per patient varied from £369 (corresponding to two infusions) when used in rheumatoid arthritis [14] to £925 (7.4 infusions or cycles) when used in combination with cyclophosphamide, doxorubicin, vincristine or prednisone therapy for diffuse large B-cell lymphoma [15] to £1,271 (six cycles) when used in nonHodgkin's lymphoma [16] . The unadjusted values reported in these studies also varied.
How Drug Administration Costs Were Measured
We found that across the 43 studies that we reviewed, there was considerable variation in the components of administration costs that were specified or included. Le et al. [7] , for example, reported administration costs of intravenous chemotherapy regimens for non-small cell lung cancer as consisting of the cost of daytime hospitalization (£422) and the cost of a medical oncology outpatient visit (£143). For oral chemotherapy regimens, the administration costs consisted of the cost of pre-therapy counselling with a hospital nurse (£18) and the cost of a general practitioner (GP) to do a local blood test (£24), but there were zero costs for physical administration. According to Ward et al. [17] , the administration cost assigned to intravenous gemcitabine was simply the costs of medical oncology outpatient visits (£153.50). On the other hand, administration costs assigned to 5-fluorouracil given by protracted venous infusion (£1,181) consisted of the costs of insertion and removal of a central line (for a day case), the cost of checking and flushing the central line or infusion pump (£235) and the costs of hospitalization for drug administration (£711), operations (£209) and concomitant medications (£26.10). According to Knight et al. [15] , chemotherapy administration costs consisted of the pharmacy cost of dispensing and doctor/nurse costs for drug administration. According to Sweetenham et al. [16] , the administration costs per patient for rituximab consisted of the inpatient stay (£423), outpatient visits (£393) and tests (£455). In this study, test costs covered both tests for chemotherapy administration and tests associated with adverse events, because of problems in separating the costs of these tests.
According to Lloyd et al. [18] , the administration costs for subcutaneous human menopausal gonadotropin and subcutaneous follicle stimulating hormone consisted of the staff costs for administering injections (£25.33) and the costs of making a clinic visit for drug administration (£28.20). According to Woolacott et al. [19] , the subcutaneous administration costs assigned to etanercept within an initial 3-month period (£293) consists of the first educational visit for etanercept self-injection (the cost of which equated to one outpatient rheumatology attendance [£131]) and four visits to a staff nurse (each visit costing £40.50) to check on treatment progress. Zero cost was assigned to the physical administration of etanercept. (See also Bravo et al. [20] .) According to Wolowacz et al. [21] , the administration cost assigned to subcutaneous low molecular weight heparin (LMWH) was the cost of an inpatient visit (£0.85, equivalent to 2.14 min of nurse time for administering LMWH injections; this applied to people eligible for total knee replacement or total hip replacement [THR] ). In the case of people undergoing THR, administration costs also included the costs of outpatient visits, which were equal to the cost of a district nurse visit per day, at £26. For people able to self-administer LMWH subcutaneously, a one-off cost for 30 min of nurse time at £11.92 for training in self-administration was incurred.
Differences in how drug administration costs were measured are also evident in Table 2 , where orally administered medications were assigned either zero or positive costs. Zero administration costs for oral medicines are plausible when one focuses on just the costs of physical administration. That is to say, it costs nothing to swallow a tablet or capsule. If drug administration costs were measured to include all relevant costs of physically administering a drug and the associated proximal costs, one would expect some positive administration costs for oral treatments. For example, according to Jit et al. [22] , the oral rotavirus vaccines Rotarix Ò and RotaTeq Ò incurred an administration cost equal to 10 min of nurse practice time. According to Le et al. [7] , the oral chemotherapies that were studied had non-zero administration costs covering the costs of outpatient visits and home care; for example, the administration cost of oral vinorelbine was not zero, as self-administration of the oral therapy at home required pre-therapy counselling with a hospital nurse and the cost of a GP to carry out blood tests.
But even if analysts and researchers focus on just physical administration, zero administration costs are not associated only with oral treatments. For instance, Morris et al. [23] assigned a zero administration cost to eptacog alfa (NovoSeven Ò ), although it was administered as an intravenous bolus injection. It appears that this was because each pack of NovoSeven Ò was sold as a bundled product consisting of one vial containing the drug, one vial containing sterile water for reconstitution, one sterile vial adapter, a sterile syringe for reconstitution and administration, a sterile infusion set and alcohol swabs. Although one can envisage some staff costs involved in the administration of eptacog alfa, it easy to see why a zero administration cost is not too unreasonable.
Indeed, a look at the spread of administration costs for each injectable route in Table 2 shows some overlap, although average estimates differed. One explanation is that there is legitimate variation in the methods of drug administration, and this is reflected in the different studies. This seems unlikely, given that we focused on studies undertaken in a single country. An alternative explanation is that studies do not provide a complete or consistent account of the costs of physically administering biologics and the proximal costs involved. There are 'hidden' costs of drug administration that some studies fail to consider. Given the observed variation in how different studies define the components of administration costs, our average estimates are necessarily imprecise (perhaps conservative) approximations.
Discussion
In this paper, we have noted that administration costs are an important component of assessing the incremental cost effectiveness of a given medical technology relative to its comparators, and that drug administration costs consist of the costs of physical administration plus proximal costs incurred before and after physical administration of a medicine. We examined these issues and found that there is variation in the range of administration costs that are included. Our review shows that the definition of administration costs for biologics is critical. Not only do administration costs vary by route of administration but, for any given route of drug administration, there is variation in the costs as a function of the method of measurement.
Differences in how studies define administration costs seems contrary to the recommendations of various methodological guidelines and quality checklists [24] that all relevant costs, beyond simple acquisition costs, should be identified, quantified and reported. A review of pharmacoeconomic evaluations conducted in Ireland and the UK by Hughes et al. [25] showed that the reporting and conduct of cost estimation is in need of improvement. The authors suggest a checklist of items which, among other things, requires that both the route of administration and costs relating to drug administration are reported. This checklist, however, separates drug administration costs from 'pharmacy charges', covering professional and dispensing fees; 'hospital pharmacy costs', covering the costs of reconstituting parenteral preparations, etc.; and 'therapeutic drug monitoring costs', covering, for example, biochemical assays or measurements of plasma concentrations and pharmacodynamic responses. If researchers are to use our framework as part of, or in addition to, their guidelines and quality checklist(s), these items will automatically be incorporated into estimates of drug administration costs. This will ensure consistency in what cost components are included or excluded. We want to emphasize that although our focus was on UK studies, the framework depicted in Fig. 1 is 'global' and applicable to non-UK settings.
On the basis of this review, the administration costs of biologics given intravenously appear to be, on average, six or eight times the costs of those given subcutaneously or intramuscularly, and biologics administered orally tend to be assigned zero administration costs. Admittedly, these average estimates suffer from being taken from a selected sample of studies that offer a comparable scale of measurement-and, of course, the literature data are not necessarily correct, given variations in how the components of drug administration costs are defined across studies. Our average estimates, nevertheless, provide a reasonable guide as to the costs of administering biologic products within the UK NHS. Yet, even for intravenous biologics, near zero administration costs are possible if manufacturers sell biologics as bundled products with some of the equipment and consumables employed in administering these products. Bundling is generally considered a strategic device for competitive (confidential) discounting or discriminatory pricing of products or services to price-sensitive purchasers [26] , but our findings suggest that there is an additional advantage from selling biologic products bundled with equipment and consumables employed in drug administration. This stems from lower administration costs, which may translate into lower total healthcare delivery costs and an increased likelihood of a biologic being considered cost effective by healthcare payers.
However, our rough estimates of drug administration costs do not consider increments or decrements in (administration) costs that might be associated with compliance issues and medication errors. The comparison by Webster et al. [27] of a mark II (pre-filled syringe) system with conventional methods of administering various drugs used in cardiac anaesthesia indicated that although use of a new safety-oriented administration system saved preparation time before and after anaesthesia, it increased overall costs per anaesthetic administered [median (range) €178 (102-428) vs. €155 (111-390), p = 0.041]. The savings in administration costs were lower than the purchase cost of the mark II system. However, this cost increment is likely to be offset by potential reductions in iatrogenic events via reductions in administration errors, i.e. avoiding cuts in glass ampoules and needle-stick injuries, violation of sterile techniques during draw-up of medicines, injection of minute glass shards, and mislabelling of syringes under the pressure of an operating theatre.
Similarly, Kruse et al. [28] argued that although a move away from intravenous single-agent therapies for breast cancer to oral formulations may save on administration costs, those savings may be offset by the added costs associated with oral agents such as noncompliance or treatment of gastrointestinal and other side effects. Also, Harley et al. [29] found that in people with rheumatoid arthritis, compliance with at least 80 % of doses administered was lower for etanercept (odds ratio [OR] 0.462, 95 % confidence interval [CI] 0.290-0.736) and for methotrexate (OR 0.385, 95 % CI 0.245-0.604) than for infliximab. This possibly reflects differences in the route and frequency of administration: infliximab is given intravenously every 8 weeks, whereas etanercept is given subcutaneously twice weekly, and patients who are anxious about self-administering subcutaneous therapies tend to miss injections and prefer intravenous infusions. The authors further argue that although other studies have reported higher administration costs for infliximab, their study showed that infliximab was associated with lower facility costs (i.e. physician costs and other fees related to drug administration) compared with etanercept. This may be due to better dosage compliance with infliximab (besides the problems of small sample sizes, inferring drug usage rates from insurance claims data and, of course, differences in how studies measure administration costs).
So what are the implications for (research into) biopharmaceutical manufacturing? Consider a pharmaceutical manufacturer, X, who has developed a biologic product, Y, and intends to launch this product on the UK NHS market. Following the work of Vernon et al. [30] , there are substantial private and societal gains in the short-or long-run from investments to lower the cost of goods (COG) for product Y. In the short-run, lower manufacturing costs may lead to lower prices and increased consumption, especially when faced with competing products. However, even if manufacturer X doesn't lower prices but keeps the cost savings, this might still improve social welfare in the long-run, as it is known that increments (or decrements) in gross price-cost margins are associated with higher (or lower) intensities of R&D [31] . That is, part of the accumulated savings or 'profits' from reducing COGs over time will be used to finance future R&D and product innovations. Indeed, Vernon et al. [30] reported that the societal gain from keeping the cost savings could be as much as 12 times that of the gain from passing cost savings on to consumers in the form of lower prices. However, that argument assumes existing demands for product Y expressed by a healthcare payer who is concerned with only the net clinical benefits offered by product Y (efficacy minus safety) and its acquisition costs, and not the total delivery costs to the healthcare system. Currently, the UK NHS relies on the National Institute for Health and Clinical Excellence (NICE) to make technology adoption decisions on its behalf, on the basis of costeffectiveness evidence, besides other factors. Following Dakin et al. [32] , the outcomes of NICE's decision making can be categorized as 'yes' (i.e. recommended for use within the EMA-approved marketing authorization), 'no' (i.e. not recommended-in which case, the demand effectively falls to zero) and 'yes, but' (i.e. recommended for restricted use-in which case, the demand will be less than was anticipated prior to market launch). In the worst-case scenario of zero demand, there will be a costly loss of on-patent sales revenue, and no societal gains in the short-or long-run from process innovations to reduce COGs. Things get better with a 'restricted' demand for product Y, but this still falls short of what is attainable in the best-case scenario. But the chosen formulation for product Y and the associated administration costs, if the full range of costs is measured, may be the key determinant of whether product Y is considered cost effective or not, the level of demand for product Y and the flow of clinical benefits to patients (see also Cheng et al. [33] ). This means that besides concentrating on selecting biologic drug candidates on the basis of net clinical benefits, 'getting a product out' and ensuring that the COG for biologic products is below defined (companyspecific) thresholds or rules of thumb, manufacturer X should pay equal attention to issues around formulation, drug administration costs and total healthcare delivery costs of product Y as early as possible over the R&D timescale.
We do not know for sure whether manufacturers of biologics routinely consider the administration costs and total delivery costs that will be borne by healthcare payers when making manufacturing and R&D decisions. It is possible that costs to healthcare payers are seldom considered by biologic companies in R&D and manufacturing decisions (or perhaps they are only when faced with therapeutic competitors), and this might reflect conflicting internal priorities or organizational disconnection between companies' manufacturing (process development) units and marketing departments. We argue that manufacturers of biologic medicines should consider formulation issues, drug administration costs and total healthcare delivery costs as early as possible in their manufacturing and R&D decisions.
Our study, however, suffers from two limitations. First, we focused on the cost of administering biologic medicines only within the UK NHS. This means that our findings may not be applicable to other country contexts or to smallmolecule chemically synthesized medicines. That said, our framework of drug administration is still useful for consistent evaluations of drug administration costs irrespective of the country context or whether the focus is on smallmolecule chemically-synthesized medicines. We recommend that future research (de novo analysis) is undertaken to assess the magnitude and importance of drug administration costs within the UK NHS, with researchers using Fig. 1 as a tool to ensure inclusion of all relevant costs of physically administering biologics and the associated proximal costs. Second, we did not assess the studies included in the review for their methodological quality, for sources of systematic error or bias (internal validity) or for their external validity. This is yet another reason why our estimates of administration costs for biologics should be considered rough approximations, and why a de novo analysis of administration costs for biologics within the UK NHS is worth pursuing.
Conclusions
Drug administration costs vary by route of administration, with average estimates for intravenous routes being higher than those for subcutaneous administration, which are higher than those for intramuscular administration, which in turn are higher than those for oral routes. These findings are, however, tied to the definitions of the components of administration costs that were used in the studies we reviewed. Within each route of administration, there is variation in costs as a function of the method of measurement. This matters, as estimates of administration costs differ across studies and according to what cost components are included or excluded. Also, our results may need to be modified in lieu of issues around medication errors and compliance, but this study has provided evidence as to how the administration costs of biologics can be lowered by selecting the most appropriate dosage form and regimen, and the most appropriate route of administration. In some cases, it is possible to lower administration costs via bundling of biologic products with equipment and consumables used in drug administration.
We argue that it is not enough to focus on getting a commercially viable product out and the market price 'right', especially when faced with healthcare payers who rely on the outputs of economic evaluation to guide their technology adoption decisions. Besides process innovation efforts to reduce the costs of goods for biologic products, manufacturers should consider (in the early phases of drug development) formulation issues and the impact on administration costs and total costs of healthcare delivery.
